Author

L. Ulicna

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Research Focus:metabolism & bioenergetics· 1 Organism:mouse· 1

Frequent Co-Authors

C. Van Rechem· 2 shared C. M. Weber· 1 shared D. E. Lee· 1 shared E. Bielczyk-Maczynska· 1 shared G. Crabtree· 1 shared G. M. Allard· 1 shared G. R. Bean· 1 shared J. P. White· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

C. Van Rechem

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Phosphoproteomic mapping reveals distinct signaling actions and activation of protein synthesis and muscle hypertrophy by Isthmin-1

M. Zhao, N. B. Dannieskiold-Samsoee, L. Ulicna, Q. Nguyen, L. Voilquin, D. E. Lee, J. P. White, Z. Jiang, N. Cuthbert, S. Paramasivam, E. Bielczyk-Maczynska, C. Van Rechem, K. J. Svensson

This study identifies distinct phosphoproteomic effects of Ism1 compared to insulin, revealing novel pathways in muscle hypertrophy and protein synthesis.

bioRxiv · May 19, 2022Cell Biology

mSWI/SNF interacts with the ribosome and its inhibition/mutations alter translation and sensitize to mTOR/PI3K inhibitors

L. Ulicna, S. C. Kimmey, C. M. Weber, G. M. Allard, S. C. Bendall, G. Crabtree, G. R. Bean, C. Van Rechem

This study shows mSWI/SNF complexes interact with the ribosome, alter translation, and increase sensitivity to mTOR/PI3K inhibitors in cancer cells with mutations.

bioRxiv · May 10, 2021 · PreprintCancer Biology